BerGenBio ASA is a clinical-stage oncology company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including immune-evasive, therapy-resistant cancers. BerGenBio is currently developing a novel investigational medicinal drug product, bemcentinib (BGB324). Bemcentinib is in the clinical stage of development, being evaluated as a treatment option in COVID-19 and various oncology settings, including acute myeloid leukemia (AML) and non-small cell lung cancer (NSCLC).
At BerGenBio, we are focused on enrolling and conducting clinical trials aimed at gaining regulatory approval, and making bemcentinib available to patients as quickly as possible. As such, we believe participation in our clinical trial is the most appropriate way to access bemcentinib at this stage of development.
BerGenBio understands the interest of patients in accessing bemcentinib outside of clinical trials and prior to regulatory approval for potentially life-threatening diseases. However, we do not offer any of our developmental medicines through expanded access programs, with the exception of patients who could benefit for continued treatment upon completion of a company-sponsored trial. We encourage those who are interested in learning more about our clinical development programs, including eligibility criteria and locations to visit www.clinicaltrials.gov.
